Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals (Nasdaq: TERN) announced on Oct 2, 2025 that it granted equity inducement awards to four new employees under its 2022 Employment Inducement Award Plan, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The Company granted options to purchase a total of 118,000 shares of common stock, with a 10-year term and an exercise price of $7.81 per share (closing price on Oct 1, 2025). The options vest over four years, subject to continued service.

Terns Pharmaceuticals (Nasdaq: TERN) announced an upcoming investor educational webinar focused on TERN-701, their investigational next-generation oral BCR-ABL inhibitor for chronic myeloid leukemia (CML). The webinar, scheduled for September 3, 2025 at 4:30 p.m. ET, will precede the anticipated Phase 1 data release in Q4 2025.

The presentation will feature key executives including CEO Amy Burroughs, CMO Emil Kuriakose, and CDO Scott Harris. They will discuss TERN-701's potential best-in-class profile, Phase 1 data benchmarks, and its positioning in the CML treatment landscape. The drug specifically targets the ABL myristoyl pocket and is being developed as an allosteric inhibitor.

Terns Pharmaceuticals (NASDAQ:TERN) reported Q2 2025 financial results and provided updates on its clinical programs. The company highlighted progress in two key areas: TERN-701 for chronic myeloid leukemia (CML) and TERN-601 for obesity.

Key financial metrics include $315.4 million in cash and equivalents, providing runway into 2028, and a net loss of $24.1 million for Q2 2025. The company plans to focus on oncology, particularly advancing TERN-701, while seeking partners for its metabolic assets.

Two major clinical readouts are expected in Q4 2025: efficacy and safety data from the Phase 1 CARDINAL trial of TERN-701, including 6-month major molecular response rates, and 12-week data from the completed Phase 2 FALCON trial of TERN-601 for obesity.

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has granted equity inducement awards to two new employees. The company's new Chief People Officer Robin Andrulevich received options to purchase 500,000 shares of common stock, while another non-executive employee received options for 125,000 shares.

The options were granted under the 2022 Employment Inducement Award Plan with an exercise price of $5.47 per share, the closing price on August 1, 2025. These 10-year term options vest over four years, contingent on continued employment.

Terns Pharmaceuticals (NASDAQ:TERN) presented positive Phase 1 data for TERN-601, their novel once-daily oral GLP-1R agonist for obesity treatment, at the 85th ADA Scientific Sessions. The 28-day study demonstrated significant dose-dependent weight loss up to 5.5%, with 67% of patients losing 5% or more body weight at the top dose.

The drug showed a differentiated safety profile with no treatment-related interruptions and over 95% of GI adverse events being mild, despite rapid dose titration. TERN-601 features unique pharmaceutical properties allowing 24-hour target coverage and can be administered with or without food and various acid-reducing medications.

The company also announced completion of enrollment for their Phase 2 FALCON trial, with 12-week topline data expected in Q4 2025.

Terns Pharmaceuticals (NASDAQ: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has announced its participation in two major investor conferences in June 2025:

• The Jefferies Global Healthcare Conference on June 5, 2025, at 11:05 a.m. ET in New York City
• The Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 4:00 p.m. ET in Miami

Both presentations will be in a fireside chat format and will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days after the events.

Terns Pharmaceuticals (NASDAQ: TERN) announced that preclinical data for its TERN-701, a next-generation allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), will be presented at the 30th European Hematology Association Congress in June 2025. The data demonstrates superior potency compared to asciminib across multiple BCR-ABL variants, including difficult-to-treat resistance mutations.

Early Phase 1 CARDINAL study results showed promising molecular responses in heavily pre-treated CML patients, with improved responses in those who had poor response to asciminib. The company expects to release additional safety and efficacy data, including 6-month major molecular response (MMR) rates, in Q4 2025.

Terns Pharmaceuticals (NASDAQ: TERN) reported Q1 2025 financial results and provided updates on its clinical pipeline. The company highlighted progress in two key programs: TERN-701 for chronic myeloid leukemia (CML) and TERN-601 for obesity. The Phase 1 CARDINAL trial for TERN-701 has advanced to dose expansion, with additional data expected in Q4 2025. The Phase 2 FALCON trial for TERN-601 is enrolling well, with top-line 12-week weight loss data anticipated in Q4 2025.

Financially, Terns reported cash and equivalents of $334.3 million as of March 31, 2025, with a runway extending into 2028. The company posted a net loss of $23.9 million for Q1 2025, compared to $22.4 million in Q1 2024. R&D expenses were $18.7 million, while G&A expenses increased to $8.7 million from $6.9 million year-over-year.

Terns Pharmaceuticals (NASDAQ: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has announced equity inducement grants to two new employees. The grants, approved under the 2022 Employment Inducement Award Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), include:

- Options to purchase 325,000 shares of Terns common stock - Exercise price of $3.56 per share (closing price on May 1, 2025) - 10-year term options - Four-year vesting period, contingent on continued employment